155 related articles for article (PubMed ID: 30414384)
1. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.
Shimura M
J Clin Pharm Ther; 2019 Apr; 44(2):243-248. PubMed ID: 30414384
[TBL] [Abstract][Full Text] [Related]
2. Optimal timing for interim analyses in clinical trials.
Togo K; Iwasaki M
J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
[TBL] [Abstract][Full Text] [Related]
3. Upstrapping to determine futility: predicting future outcomes nonparametrically from past data.
Wild JL; Ginde AA; Lindsell CJ; Kaizer AM
Trials; 2024 May; 25(1):312. PubMed ID: 38725072
[TBL] [Abstract][Full Text] [Related]
4. CP function: an alpha spending function based on conditional power.
Jiang Z; Wang L; Li C; Xia J; Wang W
Stat Med; 2014 Nov; 33(26):4501-14. PubMed ID: 25100033
[TBL] [Abstract][Full Text] [Related]
5. Overestimation of benefit when clinical trials stop early: a simulation study.
Liu S; Garrison SR
Trials; 2022 Sep; 23(1):747. PubMed ID: 36064448
[TBL] [Abstract][Full Text] [Related]
6. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
7. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
8. Flexible designs by adaptive plans of generalized Pocock- and O'Brien-Fleming-type and by self-designing clinical trials.
Hartung J
Biom J; 2006 Aug; 48(4):521-36. PubMed ID: 16972703
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority: A Systematic Review.
Shimura M; Nomura S; Wakabayashi M; Maruo K; Gosho M
JAMA Netw Open; 2020 Jun; 3(6):e208633. PubMed ID: 32573709
[TBL] [Abstract][Full Text] [Related]
10. Information time scales for interim analyses of randomized clinical trials.
Freidlin B; Othus M; Korn EL
Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
[TBL] [Abstract][Full Text] [Related]
11. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
12. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
13. A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks.
Tamhane AC; Gou J; Jennison C; Mehta CR; Curto T
Biometrics; 2018 Mar; 74(1):40-48. PubMed ID: 28589692
[TBL] [Abstract][Full Text] [Related]
14. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
Shimura M; Maruo K; Gosho M
Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian sequential design using alpha spending function to control type I error.
Zhu H; Yu Q
Stat Methods Med Res; 2017 Oct; 26(5):2184-2196. PubMed ID: 26187736
[TBL] [Abstract][Full Text] [Related]
16. Overestimation of the effect size in group sequential trials.
Zhang JJ; Blumenthal GM; He K; Tang S; Cortazar P; Sridhara R
Clin Cancer Res; 2012 Sep; 18(18):4872-6. PubMed ID: 22753584
[TBL] [Abstract][Full Text] [Related]
17. The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.
Stone A
Pharm Stat; 2010; 9(2):151-61. PubMed ID: 19771540
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of randomised controlled trials with adaptive and traditional group sequential designs - applications in cardiovascular clinical trials.
Zhang J; Saju C
BMC Med Res Methodol; 2023 Sep; 23(1):200. PubMed ID: 37679710
[TBL] [Abstract][Full Text] [Related]
19. Implementation of group sequential logrank tests in a maximum duration trial.
Lan KK; Lachin JM
Biometrics; 1990 Sep; 46(3):759-70. PubMed ID: 2242413
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Bayesian and frequentist monitoring boundaries motivated by the Multiplatform Randomized Clinical Trial.
Joo J; Leifer ES; Proschan MA; Troendle JF; Reynolds HR; Hade EA; Lawler PR; Kim DY; Geller NL
Clin Trials; 2024 May; ():17407745241244801. PubMed ID: 38760932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
